Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans

Journal of Hypertension
Lionel ColtamaiMichel Burnier

Abstract

The goal of this study was to investigate whether angiotensin II receptor blockers (ARBs) induce a comparable blockade of AT1 receptors in the vasculature and in the kidney when the renin-angiotensin system is activated by a thiazide diuretic. Thirty individuals participated in this randomized, controlled, single-blind study. The blood pressure and renal hemodynamic and tubular responses to a 1-h infusion of exogenous angiotensin II (Ang II 3 ng/kg per min) were investigated before and 24 h after a 7-day administration of either irbesartan 300 mg alone or in association with 12.5 or 25 mg hydrochlorothiazide (HCTZ). Irbesartan 300/25 mg was also compared with losartan 100 mg, valsartan 160 mg, and olmesartan 20 mg all in association with 25 mg HCTZ. Each participant received two treatments with a 1-week washout period between treatments. The blood pressure response to Ang II was blocked by more than 90% with irbesartan alone or in association with HCTZ and with olmesartan/HCTZ and by nearly 60% with valsartan/HCTZ and losartan/HCTZ (P < 0.05). In the kidney, Ang II reduced renal plasma flow by 36% at baseline (P < 0.001). Irbesartan +/- HCTZ and olmesartan/HCTZ blocked the renal hemodynamic response to Ang II nearly completely,...Continue Reading

References

Feb 15, 2001·Circulation·M Burnier
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Feb 2, 2002·Clinical Pharmacology and Therapeutics·Marc P MaillardHans R Brunner
Aug 27, 2005·Journal of the American Society of Nephrology : JASN·Roland E SchmiederChristian Delles
Feb 9, 2007·Journal of the American Society of Nephrology : JASN·Chen YuLance D Dworkin
Sep 1, 2007·Journal of Hypertension·Norman K HollenbergRicardo Rocha
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Jun 6, 2008·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN AVOID Study Investigators
Feb 13, 2009·Journal of the American Society of Nephrology : JASN·Ellen BurgessUNKNOWN SMART (Supra Maximal Atacand Renal Trial) Investigators

❮ Previous
Next ❯

Citations

Jun 22, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Antoine G SchneiderBruno Vogt
Sep 29, 2011·Integrated Blood Pressure Control·Valentina ForniMichel Burnier
Apr 15, 2011·Vascular Health and Risk Management·R Kreutz
Mar 23, 2011·Expert Opinion on Drug Metabolism & Toxicology·Michel Burnier, Grégoire Wuerzner
Aug 26, 2011·American Journal of Physiology. Renal Physiology·Michio FukudaGenjiro Kimura
Nov 6, 2015·American Journal of Physiology. Renal Physiology·Simone Costa Alarcon AriasRoberto Zatz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.